Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00316823 · ClinicalTrials.gov registry record · NA

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

A NA study, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
400
Enrollment target

NCT00316823 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 400 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00316823, a NA study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
400 participants
Enrollment target

Study Summary

RATIONALE: Finding genetic markers for thyroid cancer in a biopsy specimen may help doctors diagnose thyroid cancer. PURPOSE: This clinical trial is studying how well genetic analysis works in diagnosing thyroid cancer in patients with thyroid nodules.

Interventions

  • GENETIC gene expression analysis
  • GENETIC polymerase chain reaction
  • OTHER immunohistochemistry staining method
  • OTHER diagnostic laboratory biomarker analysis
  • GENETIC reverse transcriptase-polymerase chain reaction

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2005-07
Phase NA

What the Registry Record Tells You About NCT00316823

The ClinicalTrials.gov registry entry for NCT00316823 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.

NCT00316823 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00316823 about?

NCT00316823 is a clinical study titled "Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules". RATIONALE: Finding genetic markers for thyroid cancer in a biopsy specimen may help doctors diagnose thyroid cancer. PURPOSE: This clinical trial is studying how well genetic analysis works in diagnosing thyroid cancer in patients with thyroid nodules.

What is the current status of trial NCT00316823?

This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2005-07.

What interventions are being tested in trial NCT00316823?

The interventions under investigation include: gene expression analysis (GENETIC), polymerase chain reaction (GENETIC), immunohistochemistry staining method (OTHER), diagnostic laboratory biomarker analysis (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC).

Who is sponsoring clinical trial NCT00316823?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.